Abstract
Purpose
To investigate how revision of the organ transplant law in Japan affected lung transplantation in this country.
Methods
Lung transplant candidates registered between January, 2000 and December, 2009 were designated as the pre-revision group (n = 396) and those registered between January, 2011 and December, 2020, as the post-revision group (n = 1326). Both groups were analyzed retrospectively using data collected by the Japanese Society of Lung and Heart–Lung Transplantation.
Results
The number of patients who underwent brain-dead donor lung transplantation (BDLT) increased significantly after the law amendment (32.2 vs. 13.8%, p < 0.01). The median waiting time for BDLT was significantly reduced (708 days vs. 1163 days, p < 0.01) and the mortality rate while waiting for BDLT improved significantly after the law amendment (33.1 vs. 42.6%, p < 0.01). In the post-revision group, 18 pediatric patients underwent BDLT. The 5-year survival rates after BDLT were comparable between the groups (73.5% in the pre-revision group vs. 73.2% in the post-revision group, p = 0.32).
Conclusions
The organ transplant law revision shortened the waiting time for BDLT significantly and decreased the mortality rate while waiting for BDLT. The posttransplant outcomes in Japan remained favorable throughout the study period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chambers DC, Perch M, Zuckermann A, Cherikh WS, Harhay MO, Hayes D, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-eighth adult lung transplantation report—2021; Focus on recipient characteristics. J Heart Lung Transplant. 2021;40:1060–72.
Date H, Aoe M, Nagahiro I, Sano Y, Andou A, Matsubara H, et al. Living-donor lobar lung transplantation for various lung diseases. J Thorac Cardiovasc Surg. 2003;126:476–81.
Okada Y, Chida M, Nakajima J, Yoshino I, Shintani Y, Oto T, et al. Current status of lung transplantation in Japan—report from Japanese lung transplant registry. J Vis Surg. 2021;7:13.
Transplantation IRIODA. Newsletter of Final numbers 2021. [Internet]. https://www.irodat.org/img/database/pdf/IRODaT_Newsletter_2021.pdf. Accessed 23 Nov 2023.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
Valapour M, Lehr CJ, Skeans MA, Smith JM, Miller E, Goff R, et al. OPTN/SRTR 2019 annual data report: lung. Am J Transplant. 2021;21:441–520.
Stehlik J, Stevenson LW, Edwards LB, Crespo-Leiro MG, Delgado JF, Dorent R, et al. Organ allocation around the world: insights from the ISHLT international registry for heart and lung transplantation. J Heart Lung Transplant. 2014;33:975–84.
Hirama T, Akiba M, Watanabe T, Watanabe Y, Notsuda H, Oishi H, et al. Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study. BMC Pulm Med. 2021;21:390.
Oishi H, Okada Y, Sato M, Nakajima J, Nakajima D, Shiraishi T, et al. Prognostic factors for lung transplant recipients focusing on age and gender: the Japanese lung transplantation report 2022. Surg Today. 2023;53:1188–98.
Van Raemdonck D, Keshavjee S, Levvey B, Cherikh WS, Snell G, Erasmus M, et al. Donation after circulatory death in lung transplantation-five-year follow-up from ISHLT Registry. J Heart Lung Transplant. 2019;38:1235–45.
Starnes VA, Woo MS, MacLaughlin EF, Horn MV, Wong PC, Rowland KM, et al. Comparison of outcomes between living donor and cadaveric lung transplantation in children. Ann Thorac Surg. 1999;68:2279–83 (Discussion 2283-4).
Nakajima D, Date H. Living-donor lobar lung transplantation. J Thorac Dis. 2021;13:6594–601.
Chen-Yoshikawa TF, Sugimoto S, Shiraishi T, Minami M, Matsuda Y, Chida M, et al. Prognostic factors in lung transplantation after hematopoietic stem cell transplantation. Transplantation. 2018;102:154–61.
Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–9.
Ikezoe K, Handa T, Tanizawa K, Chen-Yoshikawa TF, Kubo T, Aoyama A, et al. Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease. PLoS ONE. 2017;12: e0183171.
Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, et al. Consensus document for the selection of lung transplant candidates: An update from the International society for heart and lung transplantation. J Heart Lung Transplant. 2021;40:1349–79.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Yoshito Imamura and his co-authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Imamura, Y., Nakajima, D., Kanou, T. et al. Effect of revised organ transplant law in Japan on lung transplantation. Surg Today (2024). https://doi.org/10.1007/s00595-024-02839-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00595-024-02839-5